Certainty in a Changing Market: Accelagen on the US Biotech Stage

Amid financial challenges and an evolving regulatory landscape in the US, Accelagen reinforced its position as a stable, strategic partner. Through key conference appearances, Accelagen showcased the benefits of Australia’s clinical trial ecosystem and its proven development model across both territories.

Accelagen Returns from Taking the Stage During US Roadshow

Wrapping up a recent US conference roadshow, headlined by Chicago BioLife and BIO2025 Conference, Accelagen set a clear example of the benefits of conducting clinical development with Accelagen for international clients. On the back of cautious investor sentiment, the trip provided an opportunity to take the temperature of the US biotech market and reinforce Accelagen as a consistent, high quality provider for clinical research in Australia and the US.

For Accelagen’s Chief Growth and Commercial Officer Mathew Palmer, the US roadshow was about building and maintaining connections. “It was really about listening and talking creatively around what clients need to do to develop their assets.”

Addressing Regulatory Challenges in Biotech

Conversations at BIO2025 Conference often focused on challenges in securing capital and uncertainty around regulatory pathways as the US market navigates a critical period. Despite these challenges, there is a clear appetite for partnerships that can help de-risk the generation of key clinical data. Australia’s consistent regulatory environment and quality of development, combined with Accelagen’s tailored service model, stood out as a strong solution.

“There’s definitely a lot of interest in Australia,” Palmer notes. “We can provide a full service offering in Australia and are one of the few CROs that still do this. We have a very high quality delivery ethos, and our asset development pipeline has resonated really well.”

Early Phase Execution and Complex Modalities

Early phase execution was another key topic of discussion, especially for complex approaches like cell therapies and radio-theranostics. Accelagen’s regulatory expertise and ability to provide full service capabilities in Australia provided a clear advantage for these programs.

Accelagen’s ability to navigate both Australian and US regulatory systems also gives sponsors more strategic flexibility, making the company a valuable link between markets. “We’ve got the ability to support both US INDs and Australian CTN or CTA schemes,” Palmer explains. “Aligning those understandings helps us to strengthen their clinical development pathway and expedite the timelines for startup.”

Why Sponsors Are Looking to Australia?

Attendees responded positively to the broader appeal of Australia, including strong clinical infrastructure, short startup times, and the R&D tax incentive. “People are loving the consistency in Australia. It's a trusted, proven environment. Our industry is fraught with risk and if you can do anything to de-risk that development pathway, it's a significant benefit for companies.”

Accelagen’s Role as a Partner in Innovation

Networking events drew in a mix of startups and established players looking to understand how Accelagen leverages its unique service model. The team at Accelagen sees its role as a genuine partner in development. “Even if the discussions do not lead to immediate awarded business, it’s great for us to think creatively and provide insights to help develop the strategy further so they are in a better position to advance their development and financing position,” Palmer says. “Our personal mission is to get new medicines, treatments, or devices to patients, and anything we can do to assist is part of our core values.”

While many attendees expressed caution over investment conditions, Palmer noted that optimism hasn’t disappeared. “Anyone can invest in an up market. Due diligence has increased in the current market, but there are still opportunities for investment. Really good investors seek solid opportunities and the mark of a great investor is a strategic investment in a down market..” Accelagen’s strength, according to Palmer, lies in linking strong assets with high quality execution and planning to help drive asset and organisational value.

Committed to Strategic, Sustainable Growth

As Accelagen expands its presence in the US, the roadshow reinforced its commitment to strategic, measured growth. The company is actively investing in staff, site networks, and partnerships designed to meet evolving market needs. By leveraging established collaborators and focusing on scalable operations, Accelagen aims to grow thoughtfully while maintaining the high quality that defines its service.

As the US biotech sector navigates the challenges ahead, Accelagen is positioning itself not just as a service provider, but as a trusted and capable partner. For Mat, the trip reinforced that clinical programs succeed when they’re supported by people who listen first. “At the end of the day,” he said, “it’s about value, real value. And that means understanding what’s needed, and then delivering on it.”

Accelagen represented Australia not just as an alternative to the US, but as a strategic alliance. With deep regulatory expertise, consistent delivery, and a focus on partnerships, Accelagen showed that it has what it takes to support clinical innovation amid market uncertainties.

‍